Loading…
← CockpitCompetitor Analysis › DNA Ginkgo Bioworks Holdings, Inc. Class AOpen in the cockpit ↗

Ginkgo Bioworks Holdings, Inc. Class ADNACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum strong 74
Mkt cap
$547M
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$27.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-48.7 pp
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$8.44
1D+1.4%
1W-17.7%
1M-14.4%
3M+21.3%
6M+9.3%
YTD+1.6%
1Y+8.5%
ATR %15.4%
Beta3.27
52w lowhigh53.7% off high

What Ginkgo Bioworks does

Employees: 485

Ginkgo Bioworks at a glance

Size Ginkgo Bioworks (DNA) is a United States Health Care company (Medical/Nursing Services) with a market value of $547M, the 2608th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.44 on 18 Nov 2026.

Performance Over six months the shares gained 9.3%, against -8.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 44.2% over the last twelve months (peer median +6.0%); the operating margin is -242.3% (peer median 8.2%).

Valuation It trades at 6.5× enterprise value to sales against a peer median of 1.4× (3rd most expensive of 21).

Capital Return on invested capital runs 48.7 points below its cost of capital (10.3% WACC).

Backlog Backlog (remaining performance obligations) was $126M at 30 Sep 2026, up 54% on a year earlier — 1.0 years of trailing revenue. Backlog detail →

Short interest Short interest is 17.1% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026DNA 104Peer median 95
Six months, rebased to 100: Ginkgo Bioworks against the median of its 20 peers (local-currency closes).

Ginkgo Bioworks financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$101M$170M$227M$251M$478M
Revenue growth—-25%-10%-47%—
Gross profit$40.7M$82.9M$137M$143M$212M
EBITDA-$193M-$255M-$397M-$601M-$2.10B
Net income-$276M-$313M-$547M-$893M-$2.10B
Free cash flow-$174M-$179M-$382M-$336M-$304M
Capital expenditure$6.56M$7.67M$62.5M$40.8M$52.3M
Total debt$397M$440M$468M$242M$443M

Quarterly statements and history in the cockpit →

Ginkgo Bioworks competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%301060127120WELLSRTAFLGTNEPHROPLUSGMRSACLIDXJSLL9860195940M12TTALOAYUPATHYROCARE300642NIOXDNA6-month return →1-month return →
Up and to the right = strong over both horizons. Ginkgo Bioworks is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%+40%2.5×5×7.5×301060127120WELLSRTAFLGTNEPHROPLUSGMRS1951JSLL195940M12TTALOAYUPATHYROCARE300642STLNNIOXDNARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ginkgo Bioworks is the large dot.

Ginkgo Bioworks competitors and peer comparison

How Ginkgo Bioworks compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ginkgo Bioworks against its 20 peers (data as of 18 Nov 2026)
MeasureDNAPeer medianRank in peer set
1-month return-14.4%-2.6%7th lowest of 21
6-month return+9.3%-8.3%4th highest of 20
Distance from 52-week high-53.7%-30.8%4th lowest of 21
Revenue growth (TTM)-44.2%+6.0%lowest of 21
Operating margin-242.3%8.2%lowest of 21
EV / Sales6.5×1.4×3rd most expensive of 21
ROIC minus cost of capital-48.7 pp-0.3 pp2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%6.5×n/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%2.3×5.9%+3.2%
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%1.2×10.1%+94.5%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%1.4×n/an/a
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%1.2×n/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%1.3×4.3%+2.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%1.5×7.8%+17.7%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%4.0×7.3%+42.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%1.3×12.3%-1.5%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%1.3×-4.7%+12.2%
M1 Kliniken M12.DEGermany$368M+1%-28%13%1.2×-5.3%+17.9%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%1.2×-5.1%+5.3%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%0.4×-14.9%+9.6%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%8.5×28.5%+10.9%
Tellgen 300642.SZChina$328M-11%+5%8%5.2×18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%0.6×5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%4.9×3.4%+15.3%

Ginkgo Bioworks backlog

Ginkgo Bioworks reported $126M of remaining performance obligations at 30 Sep 2026, up 54% from a year earlier and up 11% from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.46.

Questions

Which companies are Ginkgo Bioworks's closest peers?
The cockpit's peer set: Shanghai Labway Clinical Laboratory (301060.SZ), JS Link (127120.KS), WELL Health Technologies (WELL.TO), Strata Critical Medical (SRTA), Fulgent Genetics (FLGT), Nephrocare Health Services (NEPHROPLUS.NS), GMR Solutions (GMRS), Australian Clinical Labs (ACL.AX).
Is Ginkgo Bioworks expensive compared with its peers?
On ev / sales it trades at 6.5× against a peer median of 1.4×, 3rd most expensive of 21 in its peer set.
How has Ginkgo Bioworks stock performed?
Over six months to 18 Nov 2026 the shares returned +9.3% against -8.3% for the median peer; over one year +8.5%.
What is Ginkgo Bioworks's backlog?
Ginkgo Bioworks's remaining performance obligations (contracted revenue not yet recognised) were $126M at 30 Sep 2026, +54% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.